Physician

Jamie Burton, MD

According to 2025 Medicare claims, Jamie Burton, MD (NPI: 1073737227) practices hematology in the Little Rock-North Little Rock-Conway, AR market, with the plurality of this provider's patient population coming from Pulaski, AR. This provider's primary affiliated billing organization is CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC (NPI: 1508147810; TIN: 710437657) and primary practice location at 72205-6523. Burton is affiliated with the Main Street Rural Health Magnolia ACO LLC (ACO ID: A5400), participating under the MSSP model.

Burton's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 961 traditional Medicare patients, billed 294,276 HCPCS/CPT codes, and received $5,764,718 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,829 prescription claims across 319 beneficiaries totaling $5,005,207 in drug costs, led by Ibrance (Palbociclib). DME data shows 58 claims. Open Payments data shows 2 records totaling $41. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,916,323 to $5,764,718. Similarly, Part D prescription costs have moved sharply higher in recent years, from $592,380 to $5,005,207. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $7,245 and ending at $9,034.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	843	253,772	$2,916,323
2016	652	203,921	$1,856,278
2017	759	252,662	$2,598,079
2018	1,264	320,847	$3,840,766
2019	1,343	331,473	$4,423,777
2020	1,099	267,081	$3,518,706
2021	984	208,105	$3,297,713
2022	953	202,841	$3,335,256
2023	990	265,564	$5,036,486
2024	961	294,276	$5,764,718

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	120	1,002	$592,380
2016	167	1,334	$976,583
2017	186	1,702	$976,685
2018	251	1,820	$1,199,686
2019	244	1,748	$1,062,892
2020	239	1,709	$1,336,433
2021	265	1,908	$1,411,966
2022	261	2,162	$2,090,411
2023	297	2,436	$2,165,224
2024	319	2,829	$5,005,207

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	193	$36,570
2016	44	364	$44,891
2017	N/R	236	$21,400
2018	45	332	$33,683
2019	40	141	$16,175
2020	N/R	150	$12,410
2021	51	210	$19,656
2022	41	239	$14,703
2023	11	126	$24,381
2024	N/R	58	$1,711

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	328	508	$61
96375	Injection of additional new drug or substance into vein	225	1,438	$10
80053	Blood test, comprehensive group of blood chemicals	499	1,787	$10
36415	Insertion of needle into vein for collection of blood sample	538	1,978	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	526	2,112	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	32	896	$487,564
Keytruda	Pembrolizumab	31	651	$354,540
Cabometyx	Cabozantinib S-Malate	11	330	$285,910
Tagrisso	Osimertinib Mesylate	16	480	$267,677
Lynparza	Olaparib	13	390	$250,890

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	12	$760
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$556
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$245
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$41	Kyowa Kirin, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jamie Burton, MD?

Tedicare shows public-source Medicare data for Jamie Burton, MD (NPI 1073737227), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jamie Burton, MD have ACO affiliation data?

Jamie Burton, MD is shown with ACO affiliation data for Main Street Rural Health Magnolia ACO LLC (MSSP, ACO ID A5400).

What billing organization is linked to Jamie Burton, MD?

Jamie Burton, MD is linked to CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC (billing NPI 1508147810) in the available physician profile data.

Does Jamie Burton, MD have Open Payments data?

Jamie Burton, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.